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**Additional file 1.** Full Study Protocol.
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SG: Trial protocol, organisation of patient recruitment infrastructure, patient recruitment, submission of manuscript. WB: Trial protocol, Study Co-PI, Sponsor of the study, MB: Trial protocol, Study PI, submission of manuscript. NM: Trial protocol, acquisition of financing. PM: Trial protocol (statistical part). TI: Trial protocol (virological methods). SJ, PK, BM, TS, TE: Discussion of Trial protocol, patient recruitment. TS, TE: organisation of patient recruitment infrastructure. SD, FK: patient recruitment. The author(s) read and approved the final manuscript.
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Study results will be made available to the public by presentations at scientific meetings and by publication in a scientific journal.
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Written informed consent is obtained from all patients before study inclusion. The informed consent form was also approved by the ethics committee mentioned above. It contains detailed information about the study purpose, study design, the course of the disease, effects and side effects of Hydroxychloroquine. Patients are informed that participation in the study is voluntary and withdrawal can be done at any time.
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